Exhibit
10.3


 


EXCHANGE
AGREEMENT


This
Exchange Agreement (the “Agreement”) is entered into as of the 25th day of June, 2015, by and among Guided
Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor signatory hereto (the “Holder”),
with reference to the following facts:


A.
On May 23, 2014, pursuant to that Securities Purchase Agreement, dated as of April 23, 2014, by and among the Company and the
Holder (the “April Securities Purchase Agreement”), the Company issued to the Holder, among other things, a
senior convertible note with such aggregate outstanding principal amount as of the date hereof as set forth on the signature page
of the Holder, convertible into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”),
in accordance with the terms of thereof (the “Note”, as converted the “Conversion Shares”).


B.
On December 2, 2014, pursuant to that Securities Purchase Agreement, dated as of November 26, 2014, by and among the Company and
certain investors (the “Investors”) party thereto (the “November Securities Purchase Agreement”),
the Company issued a Warrant to Purchase Common Stock to the Holder, certain of which are currently held by the Holder in such
aggregate amounts as set forth below the signature of the Holder hereto (without regard to any limitations on exercise set forth
therein) (collectively, the “Warrant”, as exercised, the “Warrant Shares”).


C.
The Company has duly authorized the issuance to the Holder, in exchange for the Note (the “Note Exchange”),
a new senior convertible note in the form attached hereto as Exhibit A, with such aggregate initial principal amount
and accrued and unpaid interest as outstanding under the Note as of the time of issuance of the Exchanged Note, convertible into
shares of the Common Stock, in accordance with the terms of thereof (the “Exchanged Note”, as converted the
“Exchanged Conversion Shares”).


D.
The Company has duly authorized the issuance to the Holder, in exchange for the Warrant (the “Warrant Exchange”,
and together with the Note Exchange, the “Exchange”): (i) a new warrant in the form attached hereto as Exhibit
B to initially purchase such aggregate number of shares of Common Stock as issuable upon exercise of the Warrant (without
regard to any limitations on exercise set forth herein) as of December 2, 2015 in exchange for the Warrant (the “Exchanged
Warrant”, as exercised, the “Exchanged Warrant Shares”) and (ii) such aggregate number of additional
shares of Common Stock as set forth on the signature page of the Holder (the “Exchanged Shares”, and together
with the Exchanged Note, the Exchanged Conversion Shares, the Exchanged Warrant and the Exchanged Warrant Shares, the “Exchanged
Securities”).


E.
Each of the Company and the Holder desire to effectuate the Exchange on the basis and subject to the terms and conditions set
forth in this Agreement;.


F.
The exchange of the Note for the Exchanged Note and the Warrant for the Exchanged Warrant and the Exchanged Shares is being made
in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the
“Securities Act”).


E.
Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the April Securities Purchase Agreement.


NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants hereinafter contained, the parties hereto agree
as follows:


1.                 
Exchange of Securities. On the Effective Date (as defined below), pursuant to Section 3(a)(9) of the Securities
Act, the Holder hereby agrees to convey, assign and transfer the Note and the Warrant to the Company in exchange for which the
Company agrees to issue the Exchanged Note, the Exchanged Warrant and the Exchanged Shares to the Holder as follows:


(a)               
In exchange for the Note, the Company shall deliver or cause to be delivered to the Holder (or its designee) the Exchanged Note
at the address for delivery set forth on the signature page of the Holder.


(b)              
In exchange for the Warrant, on the date hereof the Company shall deliver or cause to be delivered to the Holder (or its designee)
(x) the Exchanged Warrant at the address for delivery set forth on the signature page of the Holder and (y) the Exchange Shares
to the Holder or its designee’s balance account with the Depository Trust Company (“DTC”) in accordance
with the DTC instructions delivered by the Holder to the Company on or prior to the Closing Date. On the Closing Date, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Exchanged Shares, irrespective of the date
such Exchanges Shares are credited to the Holder’s or its designee’s balance account with DTC in accordance herewith.


(c)               
The Exchanged Note, the Exchanged Warrant and the Exchanged Shares shall each be issued without any restrictive legend.


(d)              
The Holder shall deliver or cause to be delivered to the Company (or its designee) the Note and the Warrant (or affidavit of lost
Note or Warrant, in form provided upon request by the Company and reasonably acceptable to the Holder) as soon as commercially
practicable following the date hereof (the “Delivery Date”). Immediately following the delivery of the Exchanged
Note, the Exchanged Warrant and the Exchanged Shares to the Holder (or its designee), the Holder shall relinquish all rights,
title and interest in the Note and the Warrant (including any claims the Holder may have against the Company related thereto)
and assign the same to the Company, and the Note and the Warrant shall be canceled.


(e)               
Concurrently herewith, the Holder shall execute and deliver the attached Amendment to November Securities Purchase Agreement in
the form attached hereto as Exhibit C, to remove the restriction on Variable Rate Transactions (as defined therein)
and the restriction from undertaking a reverse or forward stock split or reclassification of the Common Stock.


(f)               
The Company and the Holder shall execute and/or deliver such other documents and agreements as are customary and reasonably necessary
to effectuate the Exchange.


(g)              
The Holder agrees not to transfer the Exchanged Shares (other than to an affiliate) at any time prior to the Lockup End Date (as
defined in the Exchanged Notes).


2.                 
Representations and Warranties of the Company. The Company represents and warrants to the Holder, as of the date
hereof, and as of the time of consummation of the Exchange, that:


(a)               
Organization and Qualification. The Company and each Subsidiary are duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any Subsidiary is in violation of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents except, with respect to the Subsidiaries, for violations which would not,
individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. The Company and each
Subsidiary are duly qualified to conduct its respective businesses and are in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect.


(b)              
Authorization and Binding Obligation. The Company has the requisite power and authority to enter into and perform its obligations
under this Agreement, the Exchanged Note, the Exchanged Warrant and each of the other agreements and certificates entered into
by the parties hereto in connection with the transactions contemplated by this Agreement (collectively, the “Exchange
Documents”) and to issue the Exchanged Securities in accordance with the terms hereof and thereof. The execution and
delivery of the Exchange Documents by the Company and the consummation by the Company of the transactions contemplated hereby
and thereby, including, without limitation, the issuance of the Exchanged Securities, have been duly authorized by the Board of
Directors of the Company and, other than (i) such filings required under applicable securities or “Blue Sky” laws
of the states of the United States, (ii) no further filing, consent, or authorization is required by the Company or of its Board
of Directors or its shareholders. This Agreement and the other Exchange Documents have been duly executed and delivered by the
Company and constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with
their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.


(c)               
No Conflict; Required Filings and Consents.


(i)                
The execution, delivery and performance of the Exchange Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby will not (A) result in a violation of the Certificate of Incorporation, the terms of any share
capital of the Company or any of its Subsidiaries, the Bylaws or any of the organizational documents of the Company or any of
its Subsidiaries or (B) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Company or any of its Subsidiaries is a party, or (C) result in a violation of any law, rule, regulation,
order, judgment or decree (including U.S. federal and state securities laws, rules, and regulations, and the rules and regulations
of the OTCQB (the “Principal Market”) applicable to the Company or any of its Subsidiaries or by which any
property or asset of the Company or any of its Subsidiaries is bound or affected, except, in the case of (B) or (C), as would
not be reasonably expected to result in a Material Adverse Effect.


(ii)              
Neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization or order of, or, make any filing
or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order
for it to execute, deliver or perform any of its obligations under or contemplated by the Exchange Documents, in each case in
accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations (which the Company
is required to obtain pursuant to the preceding sentence) have been obtained or effected, or will have been obtained or effected,
on or prior to the date hereof, and the Company and its Subsidiaries are unaware of any facts or circumstances that might prevent
the Company from obtaining or effecting any of the registration, application or filings pursuant to the preceding sentence. The
Company is not in violation of the listing requirements of the Principal Market and has no knowledge of any facts that would reasonably
lead to delisting or suspension of the shares of Common Stock by the Principal Market in the foreseeable future.


(d)              
No Integration. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of any of Exchanged Securities under the Securities Act or cause this offering of the Exchanged
Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable shareholder
approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system
on which any of the securities of the Company are listed or designated. None of the Company, its Subsidiaries, their affiliates
or any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require registration
of any of Exchanged Securities under the Securities Act or cause the offering of the Exchanged Securities to be integrated with
other offerings.


(e)               
Securities Law Exemptions. Assuming the accuracy of the representations and warranties of the Holder contained herein,
the offer and issuance by the Company of the Exchanged Securities is exempt from registration under the Securities Act, pursuant
to the exemption provided by Section 3(a)(9) thereof, and applicable state securities laws.


(f)               
Issuance of Exchanged Securities. The issuance of the Exchanged Note and Exchanged Warrant is duly authorized and upon
issuance in accordance with the terms of the Exchange Documents shall be validly issued, fully paid and non-assessable and free
from all taxes, liens, charges and other encumbrances with respect to the issue thereof. The issuance of the Exchanged Shares
is duly authorized and upon issuance in with the terms of the Exchange Documents will be validly issued, fully paid and nonassessable
and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof,
with the holders being entitled to all rights accorded to a holder of Common Stock. Upon issuance in accordance with the Exchanged
Note and the Exchanged Warrant, respectively, the Exchanged Conversion Shares and the Exchanged Warrant Shares, respectively,
will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and
other encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common
Stock.


(g)              
No Consideration Paid. No commission or other remuneration has been paid by Company for soliciting the exchange of the
Note for the Exchanged Note and the Warrant for the Exchanged Warrant and Exchanged Shares as contemplated hereby.


(h)              
Disclosure. Other than as set forth in the 8-K Filing (as defined below), the Company confirms that neither it nor any
other Person acting on its behalf has provided the Holder or its agents or counsel with any information that constitutes or could
reasonably be expected to constitute material, nonpublic information. The Company understands and confirms that the Holder will
rely on the foregoing representations in effecting transactions in the Exchanged Securities. All disclosure provided to the Holder
regarding the Company and its Subsidiaries, their business and the transactions contemplated hereby, including the schedules to
this Agreement, furnished by or on behalf of the Company is true and correct and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. No event or circumstance has occurred or information exists with respect to the Company
or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions, which, under applicable
law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced
or disclosed.


3.                 
Representations and Warranties of Holders. The Holder represents and warrants to the Company, as of the date hereof,
as follows:


(a)               
Organization and Authority. The Holder has the requisite power and authority to enter into and perform its obligations
under this Agreement. The execution and delivery of this Agreement by the Holder and the consummation by Holder of the transactions
contemplated hereby has been duly authorized by Holder’s board of directors or other governing body. This Agreement has
been duly executed and delivered by Holder and constitutes the legal, valid and binding obligation of Holder, enforceable against
Holder in accordance with its terms.


(b)              
Ownership of Note and Warrant. The Holder owns the Note and the Warrant free and clear of any liens (other than the obligations
pursuant to this Agreement, the Transaction Documents and applicable securities laws).


(c)               
Reliance on Exemptions. The Holder understands that the Exchanged Securities are being offered and exchanged in reliance
on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and the Holder’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Holder set forth herein and in the Exchange Documents in order to determine the availability
of such exemptions and the eligibility of the Holder to acquire the Exchanged Securities.


(d)              
Validity; Enforcement. This Agreement and the Exchange Documents to which the Holder is a party have been duly and validly
authorized, executed and delivered on behalf of the Holder and shall constitute the legal, valid and binding obligations of the
Holder enforceable against the Holder in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.


(e)               
No Conflicts. The execution, delivery and performance by the Holder of this Agreement and the Exchange Documents to which
the Holder is a party, and the consummation by the Holder of the transactions contemplated hereby and thereby will not (i) result
in a violation of the organizational documents of the Holder or (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Holder is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Holder, except
in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Holder to perform its obligations
hereunder.


(f)               
No Consideration Paid. No commission or other remuneration has been paid by the Holder for soliciting the exchange of the
Note for the Exchanged Note and Warrant for the Exchanged Warrant and Exchanged Shares as contemplated hereby.


4.                 
Disclosure of Transaction. The Company shall, on or before 8:30 a.m., New York City Time, on or prior to the fourth
business day after the date of this Agreement, file a Current Report on Form 8-K describing the terms of the transactions contemplated
hereby in the form required by the 1934 Act and attaching the Exchange Documents, to the extent they are required to be filed
under the 1934 Act, that have not previously been filed with the SEC by the Company (including, without limitation, the Exchange
Note, the Exchange Warrant and this Agreement) as exhibits to such filing (including all attachments, the “8-K Filing”).
From and after the filing of the 8-K Filing, the Company shall have disclosed all material, non-public information (if any) provided
up to such time to the Holder by the Company or any of its Subsidiaries or any of their respective officers, directors, employees
or agents. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement with respect to the transactions contemplated by the Exchange Documents or as otherwise
disclosed in the 8-K Filing, whether written or oral, between the Company, any of its Subsidiaries or any of their respective
officers, directors, affiliates, employees or agents, on the one hand, and any of the Holder or any of their affiliates, on the
other hand, shall terminate. Neither the Company, its Subsidiaries nor the Holder shall issue any press releases or any other
public statements with respect to the transactions contemplated hereby; provided, however, the Company
shall be entitled, without the prior approval of the Holder, to make a press release or other public disclosure with respect to
such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith or (ii) as is required by
applicable law and regulations (provided that in the case of clause (i) the Holder shall be consulted by the Company in connection
with any such press release or other public disclosure prior to its release). Without the prior written consent of the Holder
(which may be granted or withheld in the Holder’s sole discretion), except as required by applicable law, the Company shall
not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of the Holder in any filing, announcement,
release or otherwise.


5.                 
No Integration. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf
shall, directly or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers
to buy any security or take any other actions, under circumstances that would require registration of any of the Exchanged Securities
under the Securities Act or cause this offering of the Exchanged Securities to be integrated with such offering or any prior offerings
by the Company for purposes of the Securities Act or any applicable shareholder approval provisions, including, without limitation,
under the rules and regulations of the Principal Market and/or any exchange or automated quotation system on which any of the
securities of the Company are listed or designated.


6.                 
Listing. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the
Exchanged Conversion Shares, Exchanged Warrant Shares and the Exchanged Shares (the “Underlying Securities”)
upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is then listed or designated
for quotation (as applicable) (subject to official notice of issuance) and shall maintain such listing of all the Underlying Securities
from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common Stock’s authorization
for quotation on the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably
expected to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall pay all fees
and expenses in connection with satisfying its obligations under this Section 6.


7.                 
Fees. The Company shall reimburse Kelley Drye & Warren, LLP (counsel to the lead investor), on demand, for all
reasonable, documented costs and expenses incurred by it in connection with preparing and delivering this Agreement (including,
without limitation, all reasonable, documented legal fees and disbursements in connection therewith, and due diligence in connection
with the transactions contemplated thereby) in an aggregate amount not to exceed $20,000.


8.                 
Limited Waiver. During the period commencing as of the Delivery Date and ending as of, and including, the Lockup
End Date, the Holder hereby waives any prohibition (whether with or without consent of the Holder) set forth in the Exchange Note
or the April Securities Purchase Agreement with respect to a transaction involving the issuance of convertible securities by the
Company either (a) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading
prices of, or quotations for, the shares of the Company’s Common Stock at any time after the initial issuance of such convertible
securities, or (b) with a conversion, exercise or exchange price that is subject to being reset on more than one occasion either
(i) at some future date after the initial issuance of such convertible securities or (ii) upon the occurrence of specified or
contingent events directly or indirectly related to the business of the Company or the market for its Common Stock.


9.                 
Holding Period. For the purposes of Rule 144, the Company acknowledges that the holding period of (i) the Exchanged
Note (and upon conversion of the Exchanged Note, the Exchanged Conversion Shares) may be tacked onto the holder period of the
Note and (ii) the Exchanged Warrant (and upon exercise of the Exchanged Warrant, the Exchanged Warrant Shares (if acquired using
a Cashless Exercise (as defined in the Exchanged Warrant))) and the Exchange Shares may be tacked onto the holding period of the
Warrant, and the Company agrees not to take a position contrary to this Section 8. The Company acknowledges and agrees that in
connection with any resale of Exchanged Securities pursuant to Rule 144, the Holder shall solely be required to provide reasonable
assurances that such Exchanged Securities are eligible for sale, assignment or transfer under Rule 144, which shall not include
an opinion of Holder’s counsel. The Company shall be responsible for any transfer agent fees or DTC fees or legal fees of
the Company’s counsel with respect to the removal of legends, if any, or issuance of Exchanged Securities in accordance
herewith.


10.             
Blue Sky. The Company shall make all filings and reports relating to the Exchange required under applicable securities
or “Blue Sky” laws of the states of the United States following the date hereof, if any.


11.             
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. NOTHING IN THIS AGREEMENT
SHALL AFFECT ANY RIGHT THAT THE HOLDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AGAINST
COMPANY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND
AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.


12.             
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party; provided, that facsimile or .PDF signature pages shall be considered due execution and shall
be binding upon the signatory thereto with the same force and effect as if the signature were an original and not a facsimile
or .PDF signature.


13.             
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect
the interpretation of, this Agreement.


14.             
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).


15.             
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.


16.             
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.


17.             
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.


18.             
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns in accordance with the terms of the hereof.


19.             
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii)
upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending party); or (iii) one Business Day after deposit with an overnight courier service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:


If
to the Company:


 


Guided
Therapeutics, Inc.


5835
Peachtree Corners East


Suite
D


Norcross,
GA 30092


Tel:
770-242-8723


Fax:
770-242-8639


Attention:
Chief Executive Officer


 


with
a copy (for informational purposes only) to:


 


Jones
Day


1420
Peachtree St. N.E.


Suite
800


Atlanta,
GA 30309


Tel:
404-581-3939


Fax:
404-581-8330


Attention:
Heith D. Rodman (hdrodman@jonesday.com)


 


If
to the Holder, to its address and facsimile number set forth on the signature page of the Holder, with copies to the Holder’s
representatives set forth on the signature page of the Holder or to such other address and/or facsimile number and/or to the attention
of such other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the
effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other
communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date,
recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance
with clause (i), (ii) or (iii) above, respectively.


20.             
Remedies. The Holder and each holder of the Exchanged Securities shall have all rights and remedies set forth in
the Exchange Documents and all rights and remedies which such holders have been granted at any time under any other agreement
or contract and all of the rights which such holders have under any law. Any Person having any rights under any provision of this
Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages
by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company
recognizes that in the event that it fails to perform, observe, or discharge any or all of its obligations under this Agreement,
any remedy at law may prove to be inadequate relief to the Holder. The Company therefore agrees that the Holder shall be entitled
to seek temporary and permanent injunctive relief in any such case without the necessity of proving actual damages and without
posting a bond or other security.


21.             
Survival. The representations and warranties of the Company and the Holder contained herein and the agreements and
covenants set forth herein shall survive the Closing and delivery and issuance of the Exchanged Securities.


22.             
Indemnification. In consideration of the Holder’s execution and delivery of the Exchange Documents and acquiring
the Exchanged Securities thereunder and in addition to all of the Company’s other obligations under the Exchange Documents,
the Company shall defend, protect, indemnify and hold harmless the Holder and all of its stockholders, partners, members, officers,
directors, employees and direct or indirect Holders and any of the foregoing Persons’ agents or other representatives (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”),
as incurred, from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities
and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which
indemnification hereunder is sought), and including reasonable and documented out-of-pocket attorneys’ fees and disbursements
(the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating
to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Exchange Documents or any
other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation
of the Company contained in the Exchange Documents or any other certificate, instrument or document contemplated hereby or thereby
or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party (including for these purposes
a derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance
or enforcement of the Exchange Documents or any other certificate, instrument or document contemplated hereby or thereby, or (ii)
the status of the Holder as a holder of the Exchanged Securities pursuant to the transactions contemplated by the Exchange Documents
(unless such action, suit or claim is based upon a breach of such Holder’s representations, warranties or covenants under
this Agreement and the other Exchange Documents or any violations by Holder of state or federal securities laws or any conduct
by Holder that constitutes fraud, gross negligence, willful misconduct or malfeasance). To the extent that the foregoing undertaking
by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable under law.


23.             
Entire Agreement; Amendments. This Agreement supersedes all other prior oral or written agreements between the Holder,
the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein
and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be amended other than by an
instrument in writing signed by the Company and the Holder. No provision hereof may be waived other than by an instrument in writing
signed by the party against whom enforcement is sought.


24.             
Other Covenants. All covenants of the Company set forth in the April Securities Purchase Agreement are hereby incorporated
by reference herein, mutatis mutandis, with “Exchanged Note” replacing “Note” and “Exchanged
Conversion Shares” replacing “Conversion Shares” for all purposes thereunder. All covenants of the Company set
forth in the November Securities Purchase Agreement are hereby incorporated by reference herein, mutatis mutandis, with
“Exchanged Warrant” replacing “Warrant” and “Exchanged Warrant Shares and Exchanged Shares”
replacing “Warrant Shares” for all purposes thereunder.


25.             
Most Favored Nation. The Company hereby represents and warrants as of the date hereof and covenants and agrees from
and after the date hereof that none of the terms offered to any Person with respect to any consent, release, amendment, settlement
or waiver relating to the terms, conditions and transactions contemplated hereby (each a “Settlement Document”),
is or will be more favorable to such Person than those of the Holder and this Agreement. If, and whenever on or after the date
hereof, the Company enters into a Settlement Document, then (i) the Company shall provide notice thereof to the Holder immediately
following the occurrence thereof and (ii) the terms and conditions of this Agreement shall be, without any further action by the
Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder
shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document,
provided that upon written notice to the Company at any time the Holder may elect not to accept the benefit of any such amended
or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it
was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect
to the Holder. The provisions of this Section 25 shall apply similarly and equally to each Settlement Document.


26.             
No Commissions. Neither the Company nor the Holder has paid or given, or will pay or give, to any person, any commission,
fee or other remuneration, directly or indirectly, in connection with the transactions contemplated by this Agreement.


27.             
Termination. Notwithstanding anything contained in this Agreement to the contrary, if the Effective Date has not
occurred and the Company does not deliver the Exchange Note, the Exchanged Warrant and the Exchanged Shares to the Holder in accordance
with Section 1 hereof, then, at the election of the Holder delivered in writing to the Company at any time after the fifth (5th)
business day immediately following the date of this Agreement, this Agreement shall be terminated and be null and void ab initio
and the Note and the Warrant shall not be terminated hereunder and shall remain outstanding as if this Agreement never existed.


[The
remainder of the page is intentionally left blank]


 


 






    	 



    	 



    

 


IN
WITNESS WHEREOF, Holders and the Company have executed this Agreement as of the date set forth on the first page of this Agreement.


	 

         

         

         

         

         

         

         

         

         
	COMPANY:

        GUIDED
        THERAPEUTICS, INC.

         

         

        By:/s/
        Gene S. Cartwright

        Name:Gene
        S. Cartwright

        Title:
        President

        

        


         

	 	 


IN
WITNESS WHEREOF, Holders and the Company have executed this Agreement as of the date set forth on the first page of this Agreement.


	 

         

         

        Address
        and Delivery:

         

        c/o
        Magna Group

        5
        Hanover Square

        New
        York, NY 10004

         

        with
        a copy (for information only) to:

         

        Kelley
        Drye & Warren LLP

        101
        Park Avenue

        New
        York, NY 10178

        Attention: Michael A. Adelstein, Esq.

         

        DTC
        Delivery Information:

        


        COR
        Clearing

        DTC:
        #0052

        FBO:
        A/C #6500-0684, MG Partners II, Ltd.

         
	HOLDER:

         

        MG
        Partners II Limited

         

         

        By:/s/
        Michael Abitebol

        Name:Michael
        Abitebol

        Title:Director

        By:
        /s/ James Keys

        Name:James
        Keyes

             Title:
        Director

        Aggregate
        principal amount of Note as of date hereof: $304,094.30

        Number
        of Warrant Shares issuable upon exercise of the Warrants as of the date hereof (without regard to any limitations on exercise):
        3,850,252

        Number
        of Exchanged Shares to be issued in the Warrant Exchange: 1,000,000 [$119,000 in aggregate value, valued as of
        the closing price on the trading day immediately prior to execution]